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Background: Missing data are common in medical research, which can lead to a loss in statistical power and
potentially biased results if not handled appropriately. Multiple imputation (MI) is a statistical method, widely
adopted in practice, for dealing with missing data. Many academic journals now emphasise the importance of
reporting information regarding missing data and proposed guidelines for documenting the application of MI have
been published. This review evaluated the reporting of missing data, the application of MI including the details
provided regarding the imputation model, and the frequency of sensitivity analyses within the MI framework in
medical research articles.
Methods: A systematic review of articles published in the Lancet and New England Journal of Medicine between
January 2008 and December 2013 in which MI was implemented was carried out.
Results: We identified 103 papers that used MI, with the number of papers increasing from 11 in 2008 to 26 in
2013. Nearly half of the papers specified the proportion of complete cases or the proportion with missing data by
each variable. In the majority of the articles (86%) the imputed variables were specified. Of the 38 papers (37%) that
stated the method of imputation, 20 used chained equations, 8 used multivariate normal imputation, and 10 used
alternative methods. Very few articles (9%) detailed how they handled non-normally distributed variables during
imputation. Thirty-nine papers (38%) stated the variables included in the imputation model. Less than half of the
papers (46%) reported the number of imputations, and only two papers compared the distribution of imputed and
observed data. Sixty-six papers presented the results from MI as a secondary analysis. Only three articles carried out
a sensitivity analysis following MI to assess departures from the missing at random assumption, with details of the
sensitivity analyses only provided by one article.
Conclusions: This review outlined deficiencies in the documenting of missing data and the details provided about
imputation. Furthermore, only a few articles performed sensitivity analyses following MI even though this is strongly
recommended in guidelines. Authors are encouraged to follow the available guidelines and provide information on
missing data and the imputation process.
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Missing data are common in clinical and epidemiological
studies [1-3], and may arise for a variety of reasons that
are beyond the researcher’s control. Sometimes an indi-
vidual refuses to participate in a wave of data collection
(‘unit non-response’), or does not provide information
about a particular measure (‘item non-response’). Statis-
tical analyses that exclude individuals with missing data
result in estimates with less precision compared with the
analysis of all individuals, and more importantly, may
lead to biased inference. Applying statistical methods
that handle missing data appropriately may reduce the
bias and increase the precision of the estimates obtained
[3]. One of the main difficulties in the analysis of incom-
plete data is determining the most appropriate approach
to handle the missing data. Several statistical methods
have been proposed in the literature for handling miss-
ing data [4]. These include the simple approach of ex-
cluding all individuals with missing data (termed a
complete case analysis (CC)), single imputation methods
such as last observation carried forward (LOCF), and
more principled methods such as multiple imputation
(MI). Each of these approaches makes assumptions re-
garding the missing data that cannot be verified from
the observed data. Thus, researchers are encouraged to
carry out a sensitivity analysis to assess the robustness of
the results to plausible departures from the missing data
assumption made in the main analysis [5-8].
A review of published randomised controlled trials in
JAMA, New England Journal of Medicine, BMJ, and the
Lancet from July to December 2001, by Wood et al. [3],
observed that the majority of papers chose an inad-
equate approach for handling missing outcome data in
the analysis of randomised controlled trials, and that
sensitivity analyses were rarely performed to justify the
assumptions made in the main analysis. This review also
provided recommendations for avoiding and handling
missing data. These recommendations included report-
ing any descriptions of missing data (e.g. proportion of
missingness in each treatment arm, difference between
key baseline variables between individuals with observed
and missing outcomes, etc.), stating the missing data as-
sumptions for the statistical approach selected for hand-
ling the missing data, and performing sensitivity analyses
around the method chosen to handle the missing data
when there is a large proportion of missing data. A more
recent review of published clinical trials (2005–2012)
with missing longitudinal outcomes by Powney et al. [1]
reported ongoing inadequacies in the reporting and
handling of missing data. They found that the majority
of the published trials did not provide reasons for miss-
ingness (drop out) or justification for the methods used
to handle missing data. In line with Wood et al. and
Powney et al., the Strengthening the Reporting ofObservational Studies in Epidemiology (STROBE) state-
ment published in 2007 [9] recommends that the num-
ber of individuals with missing data for each variable of
interest should be specified as well as possible reasons
for non-participation or non-response at each stage of
the study. STROBE also states that the method for hand-
ling missing data should be detailed in the statistical
methods. A review of publications from cohort studies
with exposures measured in multiple follow-up waves by
Karahalios et al. [2], points out the continuing use of in-
appropriate methods of missing data handling and the
lack of adherence to the STROBE guidelines. Finally, a
report from the National Research Council (NRC) [8],
published in 2010, states the necessity of conducting
sensitivity analyses using different approaches to deal
with missing data to explore the robustness of conclu-
sions to alternative assumptions about the missing data.
Over recent years, multiple imputation (MI) has
gained popularity as a powerful statistical tool for hand-
ling missing data [10] and is starting to be recom-
mended by journal reviewers [7]. Although MI is
appealing and fairly easy to implement in standard stat-
istical software, it can introduce bias if not carried out
appropriately [11]. Despite the growth in popularity of
MI, a review by Mackinnon [10] highlighted that there
was inconsistent reporting of MI in research articles
published in major medical journals (i.e. JAMA, New
England Journal of Medicine, BMJ, and the Lancet) from
the earliest date of full text searching for MI until the
end of 2008. Since then, Sterne et al. [5] suggested
guidelines for the conduct and reporting of analyses
using MI, in which authors are encouraged to document
the important aspects of the implementation of the MI
procedure in order to assist readers to make informed
decisions about the analysis performed.
More recently, it is also starting to become apparent
that even when MI is carried out, it may be important to
conduct a sensitivity analysis regarding the (untestable)
missing at random assumption around MI, since it also
makes fairly restrictive assumptions about the missing-
ness [8]. However, it is unclear whether such sensitivity
analyses are being carried out after performing MI.
Previous reviews of missing data have generally fo-
cused on documenting the handling and reporting of
missing outcome data in randomised clinical trials or
missing covariate measures in cohort studies with mul-
tiple waves of data collection. In this systematic review,
our focus is more specifically on assessing the imple-
mentation and documentation of MI in both published
randomised control trials and observational studies, in
addition to the reporting of missing data when using MI.
Although we recognise the importance of correct speci-
fication of the imputation model in order to provide
valid results of MI, we focus on whether a detailed
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model and information on the imputation method are
provided, rather than judging the adequacy of the imput-
ation model.
Our systematic review extends the review proposed by
Mackinnon [10] assessing whether the reporting of MI
has improved over recent years as the popularity of this
approach has increased and guidance has appeared in
the literature. Furthermore, this review explores whether
researchers are recognising the assumptions made when
using MI and are conducting sensitivity analyses within
the MI framework to assess the impact of this assump-
tion. To do this, we report a detailed exploration of how
MI was carried out and reported within both trials and
observational studies that use MI in two high ranking
medical journals, the Lancet and the New England Journal
of Medicine, from 2008 through 2013.
The rest of this paper is set out as follows: we begin
with an overview of the steps involved in performing MI
to highlight the detail of reporting required. This is
followed by an explanation of the inclusion criteria and
extraction details for the systematic review. Finally, we
summarise the results of the review, and then end with a
discussion and draw conclusions.
Methods
Implementation of multiple imputation
MI is a sophisticated but flexible approach for handling
missing data and is broadly applicable within a range of
standard statistical software packages such as R [12],
SAS [13] and Stata [14]. MI proceeds with replicating
the incomplete dataset multiple times and replacing the
missing data in each replicate with plausible values
drawn from an imputation model. The statistical analysis
of interest (e.g. a logistic regression of binary outcome
on an exposure variable and confounders) is then per-
formed on each completed dataset separately. Finally, a
single MI estimate (and its standard error) is calculated
by combining the estimates (and standard errors) ob-
tained from each completed dataset using ‘Rubin’s rules’
[15,16]. Unlike single imputed methods, MI takes into
account the uncertainty associated with the imputed
values. The estimated variance of the overall MI estimate
allows for within-imputation (i.e. the uncertainty in the
estimate within each completed dataset) and between-
imputation (i.e. the uncertainty between the estimates
across the completed datasets) variability [15,16].
There are a number of decisions to be made in the im-
putation stage of MI which can affect the results ob-
tained. It is important to document these decisions so
that the readers can be clear about how the investigator
performed the imputation and assess the validity of the
results. For example, which variables should be included
in the imputation model, what imputation methodshould be used, and how many imputations are required.
Once these decisions have been made, it is important to
perform diagnostic checks in order to assess the adequacy
of the resulting imputation model.
Careful attention is required to select which variables
should be included in the imputation model and the
form of the variables in order to avoid misspecification
of the imputation model and produce biased results. It
has been widely recommended to include all variables
used in the analysis model (including the outcome variable
and any interactions or non-linear terms) in the imput-
ation model to ensure congeniality between the imput-
ation and analysis models. It is also important to include
auxiliary variables (i.e. those variables that are not in-
cluded in the analysis model but are potential predictors
of missingness and/or the variable with missing data) in
the imputation model which can be used to improve the
accuracy of the imputed values [17,18].
Another important decision is the method of imput-
ation. There are several methods in the statistical litera-
ture for performing MI. In univariate imputation, where
only a single variable has missing data, the imputation
model can be tailored to the variable being imputed, for
example, a linear regression model for a continuous vari-
able or a logistic regression model for a binary variable.
Predictive mean matching (PMM) [19] (where missing
data are imputed using the observed values with the
closest predictive mean from a linear regression model)
is another univariate method for imputing missing data
for continuous variables, and is less sensitive to violation
of the normality assumption than standard linear re-
gression imputation. In multivariate imputation, where
multiple variables have missing data, there are two ap-
proaches that are available in standard statistical software.
These are MI by chained equations (MICE) (also known
as fully conditional specification (FCS)) [20] where sep-
arate, conditional univariate imputation models are spe-
cified for each variable with missing data, and multivariate
normal imputation (MVNI) [21] which uses a joint normal
distribution applied to all of the variables with missing
data. Both of these approaches are used in practice and it
is currently unclear which approach is preferable [21].
With regards to the number of imputations that
should be performed, it has been suggested recently to
apply a reasonable number of imputations (>5) to avoid
producing a large Monte Carlo error [20,22,23]. White
et al. [20] argued that the number of imputations should
be at least greater than the percentage of the missing
data in the analysis (e.g. for 30% missing data at least 30
imputations should be performed).
The standard application of MI assumes that data are
‘Missing at random’ (MAR), meaning that the probability
of data being missing depends on the observed data but
not the missing data. When the underlying missing data
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that is, the probability of missingness is independent of
the observed and missing data, MI in most scenarios will
be more efficient than CC analysis [24]. Recent literature
surrounding MI recommends performing a sensitivity
analysis following MI to assess for departures from the
MAR assumption since in practice there is no way to
identify the real missing data mechanism. The idea of a
sensitivity analysis is to specify a range of possible values
which measure the departure from MAR and assess the
impact of these departures on the MI results. The weight-
ing approach (a selection based method) [25,26], and the
pattern-mixture approach [25,27] are two methods that
have been proposed in the literature for conducting sensi-
tivity analyses within the MI framework. These methods
are not readily accessible in most of the statistical software
packages at present; however, SAS has recently extended
the MI procedure for conducting sensitivity analyses to
the MAR assumption using the pattern-mixture model
approach [28]. It is currently unclear how often such sen-
sitivity analyses are conducted.Inclusion criteria and extraction details for this review
To explore the conduct and reporting of MI in the
current medical literature, we reviewed research articles
that were published between January 2008 and December
2013 in the Lancet and New England Journal of Medicine
(NEJM) in which MI was implemented. These two leading
medical journals were chosen since they were both in-
cluded in the original review by Mackinnon [10], and
their impact factor (i.e. the average number of cita-
tions of articles from a published academic journal)
over the last six years (2008–2013) remains very high
[29]. Additionally, the number of extracted articles
that used MI during this period in these two journalsTable 1 Number of articles using multiple imputation from Ja
Journal’s name
Type of studies Lancet
(n = 58)
Trials
Randomised controlled trials 35








aQuasi- experimental studies; bRetrospective studies- these are studies which perforwas 103, similar to the number of articles reviewed in
previously published reviews of reporting and hand-
ling of missing data [1-3,10,30,31].
The articles were identified using full-text search for
the term “multiple imputation” in each journal’s website.
There were no restrictions placed on the number of arti-
cles or the study design. Any supplementary materials or
web appendices provided by the publisher were included
in the review. The articles were all extracted and
reviewed by one researcher (PHR). For any papers with
uncertainty or ambiguity in the information regarding
missing data or imputation process, the information was
extracted by another researcher (JAS; ~25% of articles),
and if required, any discrepancies resolved with a third
researcher (KJL). For our systematic review, we followed
the PRISMA guidelines for transparent reporting of sys-
tematic reviews (see Additional file 1: Table S1).
The articles were classified based on the type of the
study design: (1) trials including randomised-controlled
trials (RCTs) and non-randomised controlled trials (e.g.
Quasi-experimental studies), and (2) observational stud-
ies including prospective, retrospective, cross-sectional
and case–control studies (see Table 1). The following
data were extracted from each study (where possible):
the amount of missing data (i.e. proportion of observa-
tions with missing data or the proportion of complete
cases), details on the MI procedure (including the type
of variable(s) imputed, the number of imputed variable
(s), the imputation method, the number of imputations,
the variables included in the imputation model, the
transformations applied to improve the normality of
continuous variables, the imputation software used,
whether diagnostic checks were employed to assess the
imputation model, and whether MI was conducted as a
primary or secondary analysis) and whether there were
any sensitivity analyses conducted following MI.nuary 2008 to December 2013 by type of study
New England Journal of Medicine All Studies









med a retrospective analysis of routinely collected data.
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Overall, we identified 103 published articles using MI dur-
ing the study period (Figure 1) [32-134]. Of these articles,
73 (71%) were trials (see Table 1 and Additional file 2:
Table S2).
Figure 2 shows an increasing trend over time (from
2008 to 2013) in the number of articles using MI. This
trend appears to be more visible in trials than observa-
tional studies. The key findings of this systematic review
including the details of reporting of missing data, variables
imputed, and MI procedure are summarised in Tables 2, 3
and 4, respectively
Reporting of missing data
The characteristics reported regarding the missing data are
summarised in Table 2. Overall, 69 papers (67%) provided
some information about the amount of missing data; this
includes 46 out of 73 trials (63%) and 23 out of 30 observa-
tions studies (77%). Of the 69 with information about the
amount of missing data, the proportion of complete cases
was presented or possible to infer in 41 papers (59%),
and the amount of missing data by variable was reported
or inferable in 55 papers (80%). In those with data avail-
able on the proportion of complete cases, this ranged
from 28% to 99%, with a median of 84%. The maximum
proportion of missing data for a single variable was 72%.
Very few articles (n = 13, 13%) compared the distribution
of participant characteristics (e.g. exposure, outcome,
demographic variables) between individuals with complete
and incomplete data; of these, 7 provided summary tables.
Out of 103 reviewed papers, only 20 studies (19%) provided
an explicit statement regarding the missing data assump-
tion used in the primary analysis (e.g. MCAR or MAR).Studies included 
n=103
Papers that met in
n=103
Potentially relevant articles 
extracted from the Lancet
n=58
Journal’s website se
in 2013 - Criteria: ar
between 2008 and 2
was implem
Figure 1 Search results.Variables imputed
The characteristics of imputed variables reported in the
identified articles are summarised in Table 3. In 89 articles
(86%), imputed variables were directly specified or possible
to identify from the text. The number of imputed variables
varied from 1 to 60, with the majority (n = 39) imputing
missing data in a single variable, 16 imputing missing data
for two variables and 27 imputing missing data for more
than two variables. In the remaining 7 articles the number
of imputed variables could not be determined.
The majority of trials (55/73, 75%) imputed incom-
plete outcome variables, while only a few observational
studies (9/30, 30%) imputed incomplete outcomes. In
contrast, imputing missing data in covariates was more
common in observational studies (n = 21, 70%), but less
common in trials (n = 13, 18%). Just over half of the
studies that imputed covariates imputed only one or two
covariates (18 out of 34).
Imputation details
The details of the imputation process extracted from the
identified articles are summarised in Table 4. Of the 103
articles, 40 (39%) provided no details of the imputation
method, variables used in the imputation model or the
number of imputations. Where the imputation method
was clearly specified (38/103, 37%), 20 papers (53%) used
MICE, 8 papers (21%) used MVNI, and one article (3%)
used PMM. Two papers applied MICE as well as PMM,
and the remaining 7 papers, used MI on the basis of
propensity score or regression-based imputation. For the
two main imputation methods, 12 out of 20 papers for
MICE, and 5 out of 8 papers for MVNI imputed mul-
tiple variables with missing data.in the review
clusion criteria
Potentially relevant articles extracted 




























Figure 2 Number of articles in the Lancet and New England
Journal of Medicine that used MI: overall and by study type.
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the imputation method used, this could be inferred in an
additional 21 articles using the version of the imputation
software (e.g. MI under chained equations was the only
multivariable command available in Stata 10 and earlier
versions), the default programme (e.g. IVEware, SAS
callable software application implements MI using
chained equations), or specific procedure (e.g. SAS Proc
MI via MCMC algorithm assumes multivariate normal
distribution for implementing MI).
Twelve of the articles (12%) transformed non-normal
variables prior to imputation. The logarithm (log) trans-
formation was the most commonly reported method
for handling non-normally distributed variables (n = 8);
one article used the logit transformation and the
remaining 3 articles referred to normalising transfor-
mations (n = 2) or mentioned that a transformation was
used if appropriate (n = 1).
Only 39 of the articles (38%) specified the variables in-
cluded in the imputation model. Of these, in 10 articlesTable 2 Reporting of missing data in articles using multiple im
Characteristics reported
Missingness
Availability of any information about the amount of missing data/complete c
Proportion of complete cases was stated/available
Median [Range] % complete cases
Proportion of missing by each variable was stated/available
Assessed differences between individuals with complete and incomplete dat
Provided a table
Statement regarding missing data mechanism assumed in the analysis
*Unless otherwise stated.the imputation model included auxiliary variables, in 4
the imputation model included interaction terms, and in
5 the imputation model included auxiliary variables and
interactions. In the remaining 20 articles, no further infor-
mation was provided on whether the variables included in
the imputation model were auxiliary variables or inter-
action terms. Only a few trials (n = 5) stated that they
imputed the missing data in each arm separately.
Less than half of the articles (n = 47/103, 46%) reported
the number of imputations used. The number of imputa-
tions ranged from < = 5 (11 papers) to >100 (3 papers),
with nearly half of the papers (n = 23) using 10 to 50
imputations.
Only 2 studies (2%) carried out any diagnostic
checks of their imputation model, both of which com-
pared the distribution of observed and imputed values.
Differences between the results from a complete case
analysis (or LOCF) and MI were presented in 62 arti-
cles (60%).
Seventy-six articles (74%) stated the software in which
the MI was implemented; SAS (n = 33), Stata (n = 27),
and R (n = 12) were the commonly most used packages.
Analysis status of MI
In 38 studies (37%) MI was used as the primary analysis
and in 66 studies (64%) MI was used as a secondary ana-
lysis. Where MI was implemented as a secondary analysis,
complete case analysis was the most common method for
handling missing data in the primary analysis (62 out of
66 articles).
Finally, of the 103 papers reviewed, only 3 papers (3%)
performed a sensitivity analysis following MI to investigate
the robustness of the MI estimate to departures from the
MAR assumption. Of these, only one paper provided de-
tails about the sensitivity analysis approach. The other two
papers gave no information on the method used in the
sensitivity analysis.putation
Type of studies
Trials Observational studies All studies
N (%)* N (%)* N (%)*
(n = 73) (n = 30) (n = 103)
ases 46 (63) 23 (77) 69 (67)
31 (42) 10 (33) 41 (40)
88 [47-99] 41 [28-74] 84 [28-99]
36 (49) 19 (63) 55 (53)
a in text? 8 (11) 5 (17) 13 (13)
3 4 7
13 (18) 7 (23) 20 (19)
Table 3 Reporting of variables imputed in articles using multiple imputation
Type of studies
Characteristics reported Trials Observational studies All studies
N (%)* N (%)* N (%)*
(n = 73) (n = 30) (n = 103)
Variables imputed
Variables imputed specified/available 61 (84) 28 (93) 89 (86)
Number of variable(s) imputed
1 31 8 39
2 9 7 16
>2 17 10 27
Uncleara 4 3 7
Outcome variable imputed
Yes 55 (75) 9 (30) 64 (62)
Not stated 12 (16) 2 (7) 14 (14)
No 6 (8) 19 (63) 25 (24)
Type of outcome variable imputed
Numerical 31 6 37
Categorical 16 2 18
Numerical and categorical 8 1 9
Number of imputed outcome variables
1 30 6 36
2 10 1 11
>2b 12 2 14
Uncleara 3 0 3
Covariate imputed
Yes 13 (18) 21 (70) 34 (33)
Not stated 12 (16) 2 (7) 14 (14)
No 48 (66) 7 (23) 55 (53)
Type of covariates imputed
Numerical 6 4 10
Categorical 3 8 11
Numerical and categorical 3 8 11
Uncleara,c 1 1 2
Number of imputed covariates
1 6 3 9
2 2 7 9
>2 5 8 13
Uncleara 1 3 4
*Unless otherwise stated.
aAuthors provided a generic statement regarding the imputed variables (e.g. the missing data in the covariates were imputed), and did not explicitly specify
which outcome or covariate with missing data was imputed, so the number or type of imputed variables could not be verified.
bOne article [128] imputed missing data in 5 incomplete variables for two questionnaires recorded at 6 different waves of data collection (i.e. 60 imputed variables).
cIn one paper [98], the use of MI for imputing missing data in the covariates was derived from the cited reference, so the data type of imputed variables was not clear.
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Missing data frequently occur in clinical and epidemio-
logical research. MI is now recognised as a flexible and
efficient approach to deal with missing data and iswidely employed by investigators in a wide variety of set-
tings. In this review, we show that the application of MI
has increased in research articles published in the Lancet
and NEJM over the 5-year period from 2008 to 2013.
Table 4 Reporting of MI procedure in articles using multiple imputation
Type of studies
Characteristics reported Trials Observational studies All studies
N (%)* N (%)* N (%)*
(n = 73) (n = 30) (n = 103)
Imputation details
Any imputation details provideda 60 (82) 27 (90) 87 (85)
Imputation method stated 29 (40) 9 (30) 38 (37)
MI using chained equations (MICE) 14 6 20
MI using multivariate normal model (MVNI)b 7 1 8
MI using predictive mean matching (PMM) 1 0 1
MI using regression-based imputationc 4 1 5
MI using MICE & PMMd 1 1 2
MI using propensity score 1 0 1
MI using propensity score or regression modellinge 1 0 1
General procedure/command specified 5 (7) 2 (7) 7 (7)
Proc MI 4 1 5
MI command 0 1 1
Model-based MIf 1 0 1
Imputation method inferred 11 (15) 10 (33) 21 (20)
MICE (SAS- IVEware) 1 2 3
MICE (Stata- pre V11) 1 2 3
MICE (Multiple packageg) 1 0 1
MVNI (SAS- pre V9.3-imputed more than 1 variable) 5 1 6
MVNI (R-Amelia II) 0 2 2
MVNI (S-plus) 2 0 2
Regression-based imputation (SAS pre V9.3-imputed 1 categorical variable) 1 3 4
Non-normal variables transformed prior to imputation 6 (8) 6 (20) 12 (12)
Log transformationh 4 4 8
Logit transformation 0 1 1
General comment about applying normalising transformation 2 1 3
Provided details on the variables included in the imputation model 26 (36) 13 (43) 39 (38)
Included auxiliary variable(s) 6 4 10
Included interaction term(s) 2 2 4
Included auxiliary variable and interaction 3 2 5
No information provided on auxiliary variables and interaction terms 15 5 20
Number of imputations 28 (38) 19 (63) 47 (46)
≤5 8 3 11
10 6 3 9
11-50 8 6 14
100 4 6 10
>100 2 1 3
Carried out diagnostic checks of the imputation modeli 0 (0) 2 (7) 2 (2)
Assessed differences between results obtained from CC/LOCF and MI in the text/tablej 45 (62) 17 (57) 62 (60)
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Table 4 Reporting of MI procedure in articles using multiple imputation (Continued)
Software details
Imputation software statedk,l 51 (70) 25 (83) 76 (74)
SAS 23 10 33
Stata 18 9 27
R 6 6 12
Other packages (SOLAS, S-plus, SPSS) 4 0 4
Analysis status of MI
MI used in the primary analysis 26 (36) 12 (40) 38 (37)
MI used as a secondary analysis 47 (64) 19 (63) 66l (64)
Methods used for primary analysis if MI applied as a secondary analysis
Complete case analysis (CC)m,n 43 19 62
Last observation carried forward (LOCF) 4 0 4
Sensitivity analysis following MI 3 (4) 0 (0) 3 (3)
Pattern-mixture model approach 1 0 1
Selection model approach 0 0 0
Performed but the method not statedo 2 0 2
*Unless otherwise stated.
Abbreviations: MI- multiple imputation, MICE- multiple imputation by chained equations, MVNI- multivariate normal imputation, PMM- predictive mean matching,
MCMC- Markov chain Monte Carlo, CC- complete case, LOCF- last observation carried forward.
aAny information provided by the authors with regard to the imputation process. Note: a general procedure/command stated by the authors, and the imputation
methods that were inferred by the reviewers are not included in this category.
bIn five articles [35,61,68,90] MI via MCMC algorithm was used for imputing missing data.
cIn three articles [40,47,84], logistic regression method and in two articles [39,113], linear regression method were stated as a imputation method for handling missing data.
dTwo articles [61,93] imputed one or two variables with missing data under PMM (because of non-normality), and imputed other incomplete variables under MICE.
eOne article [91] stated that MI was used on the basis of either propensity scoring or regression modelling for imputation of missing data in the primary and
secondary outcome measures.
fOne article [51] stated that model-based MI was used to account for missing data in the clinical outcome.
gIn one article [77] multiple packages were used for the analyses, i.e. SPSS version 15.0 and Stata version 10.1. The default imputation method in either of these
packages (given the specified versions) was chained equations.
hOne article [93] used both the square root and log transformations for non-normally distributed variables.
iBoth articles [82,130] compared the observed and imputed data.
jThe MI estimates were not provided in 6 articles [34,37,81,85,87,120], instead a comparison of the results between the different approaches for dealing with the
missing data was commented on in the text (e.g. the analysis of complete cases and the imputed data provided the same results).
kFor eight articles [59,77,81,88,94,96,115,127] it was not possible to extract this information because multiple packages for the statistical analyses were mentioned
with no explicit statement regarding which package was used for imputation.
lThose articles that did not provide the name of the imputation software (R, Stata, SAS, etc.), but instead gave the name of the procedure/application used for
imputing missing data (e.g. Amelia II, IVEware) were also included here.
mOne article [99] used MI as well as CC for primary analysis to impute the missing confounder values (with no imputation of missing data in the exposure and
outcome), and used MI again as a sensitivity analysis to impute missing data in all confounders and the outcome (but not the exposure), as well as a CC.
nTwo articles [40,100] used LOCF for the secondary analysis as well as MI; one of them described the MI as a sensitivity analysis.
oA general statement was made about performing a sensitivity analysis but the results of the details were not provided.
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since the previous review by Mackinnon [10], that also ob-
served a significant increase in use of MI between 2005 and
2008 in articles published in four major medical journals.
We identified 103 studies from these two high ranking
journals that implemented MI in the statistical analyses.
These papers represent approximately 3% of the total 3815
original research articles published between January 2008
and December 2013 (i.e. 58/1705 papers in the Lancet and
45/2110 papers in the NEJM) [29]. Since the majority of
the identified papers were trials where the missing out-
come variables were imputed, we re-emphasise the need
for trialists to consider schemes to encourage maximum
follow-up of participants at the pilot phase and design
stage of the study [6]. This may minimize the amount and
potential impact of missing data.Despite the presence of guidelines and recommenda-
tions for clear documentation around the reporting of
missing data [1-3,5,9,10,30,31], there remains poor report-
ing of the amount of missing data with only half of the ar-
ticles in this review providing the proportion of the
complete cases or the proportion of missing data for each
variable of interest in the manuscript. This observation is
consistent with the finding of Mackinnon [10], who found
that just over half of the articles did not provide any infor-
mation about the amount of missing data. When perform-
ing MI, one should clearly report the amount of missing
data for each variable included in the analysis, or at least,
state the number of cases with complete observations.
Providing this information helps the reader to assess the
validity of the results since a larger proportion of missing
data may introduce a greater bias in the analysis.
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and incomplete data can be used to examine the validity
of the MCAR assumption; however, few articles compared
the characteristics of participants with complete and in-
complete data. Moreover, less than one-third of the pub-
lished papers had a statement about the assumption made
regarding the missing data within the analysis. Collecting
information on reasons for missing data is very valuable
and can help determine the most plausible assumption
underlying the missing data. Since the standard applica-
tion of MI assumes that data are MAR, it is important for
investigators to acknowledge this assumption when using
MI and justify it. Given it is not possible to assess the
validity of the MAR assumption, it is also important to
assess the sensitivity of the results to this assumption
by making alternative assumptions about the missing
data, for example that data are missing not at random
(MNAR), that is allowing the missingness to depend on
the unobserved data.
Previously published reviews and guidelines of hand-
ling missing data suggest the importance of providing
adequate information on the imputation process used in
MI [5,10]. However, this was one of the greatest weak-
nesses we found in our review. While details of the im-
putation method were available in just over one-third of
the articles, this information was often not explicitly
stated and was instead derived from the details of the
imputation software. It is important that the researcher
performing MI recognise the impact of decisions made
in setting up the imputation model on the MI results.
Presenting details on how MI was carried out may provide
insight regarding the distributional assumptions made for
variables with missing data, so that the validity of the
results can be assessed. Detailed information, required
for all statistical analyses, also ensures reproducibility
of the results.
In our review, approximately one-third of articles
clearly specified the variables included in the imputation
model, and only half of these commented on the inclusion
of auxiliary variables or interaction terms. Obtaining infor-
mation on auxiliary variables that are highly associated
with the missingness mechanism and the incomplete
variable, and incorporating them into the imputation
model can make the MAR assumption more plausible.
In addition, it can improve the accuracy of the imputa-
tions, and as a result, may reduce the bias and increase the
precision of the estimates.
In line with the Mackinnon’s review [10], we found that
less than half of the articles stated the number of imputa-
tions, with nearly half using 10 to 50 imputations. As men-
tioned earlier, applying an adequate number of imputations
is recommended in order to avoid producing a large Monte
Carlo error. Therefore, stating the number of imputations
along with the percentage of missing data within eachvariable can help readers make a better judgment about the
accuracy of the MI results.
Despite the recent acknowledgement about the import-
ance of carrying out diagnostic checks of imputation
models [135-138], only two articles carried out any form of
diagnostic checking, both of which compared the distribu-
tion of the observed and imputed values.
The importance of reporting and explaining differ-
ences between the results of complete case analysis and
MI was pointed out by Sterne et al. [5], and have been
recently emphasised by Powney et al. [1] in a supporting
guidance for handling missing data in longitudinal trials.
However, our review shows that just under two-third of
articles compared the estimates derived from a complete
case analysis and MI.
While the findings of the paper published by Mackinnon
[10] showed that MI was implemented as the primary ana-
lysis in just over half of the identified articles, we observed
that MI was adopted as the secondary analysis in just
under two-third of the studies, with complete case analysis
generally being used as the primary analysis.
Disappointingly, the majority of the reviewed articles
failed to recognise the importance of conducting sensitiv-
ity analyses regarding the MAR assumption following MI.
More specifically, only three articles explored the sensitiv-
ity of the results to departures from MAR, of which only
one article [128] provided details of the estimates derived.
We understand that there is a lack of explicit guidelines in
the literature for conducting sensitivity analyses within the
MI framework. The development of this area is a subject
of ongoing research. We believe that performing sensi-
tivity analyses regarding the MAR assumption post-MI
should be regarded as an essential part of the analysis
to assess the robustness of the conclusions to plausible
departures from this critical assumption.
It is important to acknowledge that many journals
have strict word limits for original research articles, in-
cluding a maximum number of tables and figures that
can be included. For example, in the Lancet the word
limit is 3000 words, and in the NEJM it is 2700 words
for Original and Special articles. This makes it difficult
to include all of the details surrounding the imputation
procedure. However, this information can be reported in
a previously published “baseline” or “protocol” paper, or
included as online supplements, especially in such journals
with very tight word limits. In his recent paper, Ware [7]
suggested some improvements in journal policies re-
garding the reporting of clinical trials and observational
studies in presence of missing data, in addition to the
documentation of details about the methods for handling
missing data. As noted by Ware [7], journal authors will
be required to state clearly the assumptions made about
the missing data and justify them, and may be requested to
conduct sensitivity analyses where appropriate. In addition,
Hayati Rezvan et al. BMC Medical Research Methodology  (2015) 15:30 Page 11 of 14authors will be expected to provide supplementary appen-
dices in which the details of the method for analysis of
missing data are clearly explained. It is important to note
that while just over two-thirds of the identified articles in
this review included supplementary materials or web ap-
pendices, very few articles provided a complete description
of the missing data and the MI procedure according to the
available reporting guidelines.
Conclusions
This review of articles published (in the Lancet and NEJM)
in the past 5 years (2008–2013) has highlighted the
continued inadequacy of reporting information about
missing data and the MI procedure in research articles
that use MI. Although our review showed improvements in
reporting since the Mackinnon review of articles published
between 1994 (earliest MI publication) and 2008, many
articles are still not following the guidelines and recom-
mendations for the reporting of missing data and statistical
analyses using MI.
It is essential that researchers are aware of the issues that
may arise when implementing MI, and more importantly
that biased and imprecise results may be obtained if the
imputation model is misspecified. Authors are encouraged
to provide information on missing data, include details of
the analyses when using MI, explore the impact of missing
data on their results, and assess the sensitivity of the MI re-
sults to plausible departures from the MAR assumption.
Providing detailed information on all of the above allows
readers to make an informed decision about the quality of
the study results, appropriateness of the imputation
process, and validity of the results obtained from MI.
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